No Data
No Data
Voluntary disclosure announcement of Cabio Biotech (Wuhan) Co., Ltd.'s expected performance growth in the first half of 2024.
Cabio Biotech (Wuhan) actively participates in customer research and development work related to adding HMO products to the formula.
Cabio Biotech (Wuhan) stated on the investor interactive platform on July 4 that currently, the first domestic infant formula milk powder containing HMO has not yet been launched, and core customers are actively promoting the registration of their newly added HMO infant formula milk powder formulas. The company has been deeply cultivating the infant and toddler formula field for many years, has a strong customer base and stable customer cooperation relationship, and has initially established a certain scale of production capacity while accelerating the company's own product regulatory application. At the same time, the company has reached strategic cooperation agreements with downstream core customers, actively participated in customer research and development work on adding HMOs products, and made preparations in advance.
Cabio Biotech(Wuhan) (688089.SH) plans to distribute a dividend of 0.2 yuan per share for the 2023 fiscal year, with ex-rights and ex-dividends on June 26th.
Cabio Biotech (Wuhan) (688089.SH) announced that it plans to distribute a cash dividend of 0.2 yuan per share for the 2023 fiscal year, including...
Jia Biyou (688089.SH): Based on synthetic biology technology, the company has now developed a series of HMO products
Gelonghui, May 16, 丨 Jia Biyou (688089.SH) said on the investor interactive platform that with technological innovation as the fundamental driving force, the company has opened up the entire synthetic biology technology chain, gradually formed a biological data analysis and processing platform with computational biology and bioinformatics as the core technical capabilities, a biosynthetic platform with genetic engineering, metabolic engineering, enzyme engineering, and cell engineering as the core technical capabilities, and visual analysis of cell biology, biomedicine, and multidimensional omics as the core competencies. From product development to application technology, the company's synthetic biology research and development technology Capabilities have been further improved
Jia Biyou (688089.SH): Major customers have proposed clear plans to replace DHA in seaweed oil with DHA in fish oil, and the company is also actively participating
Gelonghui, May 16 | Jia Biyou (688089.SH) said on the investor interactive platform that the company's product pricing adopts the overall strategy of “one household, one policy, one product, one case”, and that there are differences in pricing for customers in different regions and application fields. In recent years, due to the influence of factors such as marine pollution and increased global ESG requirements, the global trend of replacing DHA in fish oil has accelerated. In the field of infant formula, major customers have proposed clear plans to replace DHA in seaweed oil with DHA in fish oil, and the company is also actively participating.
Jia Biyou (688089.SH): The company is based on synthetic biology
Gelonghui, May 16, 丨 Jia Biyou (688089.SH) said on the investor interactive platform that the company is based on synthetic biology. Currently, its main products include polyunsaturated fatty acid ARA, algae oil DHA, terpenoid substances beta-carotene, astaxanthin, etc., and the sugar substances SA and hMOS, etc., which are widely used in infant formula, health food, animal nutrition, personal care and beauty. It is also continuously expanding into biomedicine, biomaterials, biological agriculture, etc. based on the underlying technical characteristics of synthetic biology. field.
No Data